Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Critical Care (London, England)
|
April 20, 2010
Inter-rater reliability of the Full Outline of UnResponsiveness score and the Glasgow Coma Scale in critically ill patients: a prospective observational study
Michael Fischer, Stephan Rüegg, Adam Czaplinski, et al.
Muscle & Nerve
|
February 22, 2008
ALSFRS and appel ALS scores: discordance with disease progression
Andrei Voustianiouk, Gregory Seidel, Janki Panchal, et al.
Annals of Neurology
|
January 26, 2005
IgM deposits on skin nerves in anti-myelin-associated glycoprotein neuropathy
Raffaella Lombardi, Beat Erne, Giuseppe Lauria, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
January 15, 2016
Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern
Björn Zörner, Linard Filli, Katja Reuter, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical
|
October 13, 2023
Tolerability of subcutaneous ofatumumab with long-term exposure in relapsing multiple sclerosis
John Kramer, Ralf Linker, David Paling, et al.
Multiple Sclerosis and Related Disorders
|
December 12, 2018
Patterns of care for Multiple Sclerosis in a setting of universal care access: A cross-sectional study
Laura Barin, Marco Kaufmann, Anke Salmen, et al.
CNS Neuroscience & Therapeutics
|
April 24, 2013
Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS)
Jana Lizrova Preiningerova, Ulf Baumhackl, Tunde Csepany, et al.
Der Nervenarzt
|
July 23, 2021
[Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)]
Heinz Wiendl, Ralf Gold, Thomas Berger, et al.
Therapeutic Advances in Neurological Disorders
|
August 23, 2021
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
Heinz Wiendl, Ralf Gold, Thomas Berger, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Critical Care (London, England)
|
April 20, 2010
Inter-rater reliability of the Full Outline of UnResponsiveness score and the Glasgow Coma Scale in critically ill patients: a prospective observational study
Michael Fischer, Stephan Rüegg, Adam Czaplinski, et al.
Muscle & Nerve
|
February 22, 2008
ALSFRS and appel ALS scores: discordance with disease progression
Andrei Voustianiouk, Gregory Seidel, Janki Panchal, et al.
Annals of Neurology
|
January 26, 2005
IgM deposits on skin nerves in anti-myelin-associated glycoprotein neuropathy
Raffaella Lombardi, Beat Erne, Giuseppe Lauria, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
January 15, 2016
Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern
Björn Zörner, Linard Filli, Katja Reuter, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical
|
October 13, 2023
Tolerability of subcutaneous ofatumumab with long-term exposure in relapsing multiple sclerosis
John Kramer, Ralf Linker, David Paling, et al.
Multiple Sclerosis and Related Disorders
|
December 12, 2018
Patterns of care for Multiple Sclerosis in a setting of universal care access: A cross-sectional study
Laura Barin, Marco Kaufmann, Anke Salmen, et al.
CNS Neuroscience & Therapeutics
|
April 24, 2013
Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS)
Jana Lizrova Preiningerova, Ulf Baumhackl, Tunde Csepany, et al.
Der Nervenarzt
|
July 23, 2021
[Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)]
Heinz Wiendl, Ralf Gold, Thomas Berger, et al.
Therapeutic Advances in Neurological Disorders
|
August 23, 2021
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
Heinz Wiendl, Ralf Gold, Thomas Berger, et al.
Page
of 2